← Leaderboards
Theodore E Liston
Astrocyte Pharmaceuticals, Inc.
$4,495,704
Attributed
$4,495,704
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.5M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,495,704 · 2
By mechanism
R44$4,495,704 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Drug Kinetics”
- Leonard Freedman · Leidos Biomedical Research, Inc.$241,865,009
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,714,869
- Yunda Huang · Fred Hutchinson Cancer Center$53,780,853
- Leonard Freedmand · Leidos Biomedical Research, Inc.$52,916,621
- Susan Abushakra · Alzheon, Inc.$47,690,244
- Kathleen Maletic Neuzil · Emory University$27,014,427
Research focus
Drug KineticsEmotionalCognitiveDoseCellular TargetingEdemaAffectBrain TissueDisabilityAmericanCause Of DeathCell TypeClinical TrialsCessation Of LifeAreaAstrocytesAgonistAttentionCanis FamiliarisCritical PathwaysBrainBrain ConcussionAcuteEpidemic
Grant awards (3)
Preclinical Efficacy and Safety Evaluation of Oral AST-004 for Moderate Traumatic Brain Injury (TBI)$1,499,886
R44 · FY2025 · NS · contact PI
Preclinical development of AST-004 for astrocyte-mediated treatment of TBI.$1,499,342
R44 · FY2019 · NS · contact PI
Preclinical development of AST-004 for astrocyte-mediated treatment of TBI.$1,496,476
R44 · FY2018 · NS · contact PI